Milestone PharmaceuticalsMIST
MIST
About: Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
Employees: 33
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
33% more capital invested
Capital invested by funds: $43.6M [Q3] → $57.9M (+$14.3M) [Q4]
9% more funds holding
Funds holding: 43 [Q3] → 47 (+4) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 14
7.79% less ownership
Funds ownership: 53.83% [Q3] → 46.04% (-7.79%) [Q4]
45% less call options, than puts
Call options by funds: $144K | Put options by funds: $264K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$10
1,025%
upside
Avg. target
$10
1,025%
upside
High target
$10
1,025%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Patrick Trucchio 15% 1-year accuracy 28 / 186 met price target | 1,025%upside $10 | Buy Maintained | 1 Apr 2025 |
Financial journalist opinion
Based on 7 articles about MIST published over the past 30 days
Neutral
Seeking Alpha
2 weeks ago
Stock Picks From Seeking Alpha's March 2025 New Analysts
In March, we welcomed 30 new analysts to Seeking Alpha, and in this article we are showcasing their stock picks and investment strategies. Our analysts covered a diverse set of industries—including IT, financials, utilities, materials, and mining—and provided ratings ranging from Strong Sell to Strong Buy. Top picks include C3.ai, Robinhood, Central Puerto, CF Industries, and Kyndryl.
Neutral
Zacks Investment Research
2 weeks ago
MIST Stock Falls 66% Following Complete Response Letter for Cardamyst
Milestone Pharmaceuticals faces an FDA setback for its PSVT nasal spray. The company coordinates with regulatory authorities to resolve CRL issues.
Negative
Market Watch
3 weeks ago
Milestone Pharmaceuticals Shares Hit New Low After FDA Rejects Etripamil
Milestone Pharmaceuticals shares collapsed on Friday after the U.S. Food and Drug Administration once again turned away the biopharmaceutical company's proposed etripamil nasal spray to treat a type of irregular heartbeat.
Negative
Reuters
3 weeks ago
US FDA declines to approve Milestone Pharma's heart rhythm nasal spray
The U.S. Food and Drug Administration has declined to approve Milestone Pharmaceuticals' nasal spray to treat a type of heart condition, the company said on Friday.
Neutral
GlobeNewsWire
3 weeks ago
FDA Issues Complete Response Letter for Etripamil for PSVT
CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for CARDAMYST™ (etripamil) nasal spray, a prescription medication in development for the conversion of acute episodes of PSVT to sinus rhythm in adults.
Positive
Seeking Alpha
4 weeks ago
Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers
In December 2023, Milestone Pharmaceuticals received an RTF letter from the FDA for insufficient TEAE data in their NDA filing, which precipitated a rapid decline in its share price. With an upcoming PDUFA in the PSVT indication, the company is approaching a binary event that will largely determine its future on the market. Considering Milestone's 2,000 patients worth of drug data across five clinical trials, we believe approval to be imminent for Etripamil and recommend a long position.
Neutral
GlobeNewsWire
4 weeks ago
Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology
MONTREAL and CHARLOTTE, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present a moderated poster presentation at the American College of Cardiology annual meeting (ACC25), to be held March 29th to 31st, 2025 in Chicago, Illinois.
Neutral
GlobeNewsWire
1 month ago
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
FDA PDUFA review goal date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)
Neutral
GlobeNewsWire
1 month ago
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MONTREAL and CHARLOTTE, N.C., March 04, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 94,000 options (the “Options”) to purchase the Company's common shares, pursuant to the Company's 2021 Inducement Plan (the “Plan”), previously approved by the Company's Compensation Committee and the Board of Directors, as a material inducement to employment of four new hires.
Neutral
GlobeNewsWire
1 month ago
Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
MONTREAL and CHARLOTTE, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, will present at the TD Cowen 45th Annual Health Care Conference, to take place from March 3-5, 2025 in Boston.
Charts implemented using Lightweight Charts™